Zur Rose Group AG publishes invitation to the Annual General Meeting of Shareholders on 23 May 2019
Zur Rose Group AG today sent out to its shareholders the invitation to the Annual General Meeting of Shareholders on 23 May 2019. In addition to the normal business, there are a number of further items on the agenda.
In the event that the Federal Act on Tax Reform and AHV Financing (TRAF) is approved by Swiss voters on 19 May 2019, Zur Rose Group AG intends to convert some of the existing capital reserves into share capital, so that after the new law comes into effect it can continue to make distributions free of withholding tax by gradual par value repayments by way of capital reduction. With this in mind, the Board of Directors proposes to the General Meeting of Shareholders an ordinary capital increase by increasing the par value of registered shares issued by CHF 24.25 from CHF 5.75 today to CHF 30.00 per share without issuing any new shares. As the par value increase is financed from the existing capital contribution reserves of the Company, there is no need for the shareholders to make any contributions or other payments.
At the same time, the Board of Directors proposes an increase in the conditional share capital by 176,643 registered shares to 200,000 registered shares in order to issue shares for employee participation programmes. In addition, it proposes to create new share capital in the amount of 1,308,880 registered shares to expand Zur Rose Group AG's financial flexibility.
As already announced on 15 April 2019, the Zur Rose Group is proposing that Tobias Hartmann, Dr Christian Mielsch and Florian Seubert be elected to the Board of Directors as new members. The nomination is intended to add proven expertise in technology, trading and finance to the company's highest board.
The invitation to the General Meeting of Shareholders of Zur Rose Group AG with the full agenda and explanations from the Board of Directors plus further information is available at www.zurrosegroup.com | Investors & Media | General Meeting of Shareholders or at the following link https://www.zurrosegroup.com/websites/zurrosegroup/English/2070/general-meeting-of-shareholders.html
Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: email@example.com, phone: +41 58 810 11 49
Lisa Lüthi, Head of Corporate Communications
Email: firstname.lastname@example.org, phone: +41 52 724 08 14
23 May 2019 Annual General Meeting
21 August 2019 2019 Half-Year Results
23 October 2019 Q3/2019 Trading Update
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management and actively promotes its positioning as a comprehensive, integrated cross-service healthcare platform. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry.
The Zur Rose Group is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. The company employs over 1,300 people at various locations and generated a turnover of CHF 1,207 million in the 2018 financial year. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in July 2018 is also listed on the SIX Swiss Exchange (securities number 42146044, ISIN CH0421460442, ticker ZRO18). Further information at zurrosegroup.com